| 1 | Targeting molecular pathways to control immune checkpoint inhibitor toxicities | 8.4 | 37 | Citations (PDF) |
| 2 | PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells | 3.1 | 1 | Citations (PDF) |
| 3 | Tumor Cell–Intrinsic
Decr2
Regulates Ferroptosis and Immunotherapy Efficacy | 3.1 | 1 | Citations (PDF) |
| 4 | Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy | 4.4 | 25 | Citations (PDF) |
| 5 | Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy 2024, 12, e009588 | | 5 | Citations (PDF) |
| 6 | Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools | 0.8 | 1 | Citations (PDF) |
| 7 | Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events | 2.4 | 19 | Citations (PDF) |
| 8 | CXCL9 and CXCL10 bring the heat to tumors | 8.9 | 210 | Citations (PDF) |
| 9 | Checkpoint Blockade–Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines | 3.1 | 87 | Citations (PDF) |
| 10 | Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity | 8.2 | 47 | Citations (PDF) |
| 11 | Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade | 15.0 | 84 | Citations (PDF) |
| 12 | Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit | 1.1 | 7 | Citations (PDF) |
| 13 | Cancer and the Microbiome—Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy | 0.9 | 357 | Citations (PDF) |
| 14 | COVIDOSE: A Phase II Clinical Trial of Low‐Dose Tocilizumab in the Treatment of Noncritical COVID‐19 Pneumonia | 2.7 | 53 | Citations (PDF) |
| 15 | Sensitive detection and quantification of SARS-CoV-2 in saliva | 2.7 | 32 | Citations (PDF) |
| 16 | Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients | 1.7 | 9 | Citations (PDF) |
| 17 | Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma 2021, 9, e002417 | | 43 | Citations (PDF) |
| 18 | Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma | 1.0 | 4 | Citations (PDF) |
| 19 | A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab 2020, 8, e000380 | | 12 | Citations (PDF) |
| 20 | ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients | 3.5 | 67 | Citations (PDF) |
| 21 | Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells | 11.0 | 116 | Citations (PDF) |
| 22 | Epigenetic Control of
Cdkn2a.Arf
Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion | 4.2 | 31 | Citations (PDF) |
| 23 | STING pathway agonism as a cancer therapeutic | 6.1 | 333 | Citations (PDF) |
| 24 | Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma 2019, 7, | | 140 | Citations (PDF) |
| 25 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study | 14.5 | 940 | Citations (PDF) |
| 26 | Exploring the emerging role of the microbiome in cancer immunotherapy 2019, 7, | | 288 | Citations (PDF) |
| 27 | Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma 2019, 7, | | 81 | Citations (PDF) |
| 28 | Brain Tumor Microenvironment and Host State: Implications for Immunotherapy | 4.5 | 316 | Citations (PDF) |
| 29 | High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions | 3.1 | 52 | Citations (PDF) |
| 30 | WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers | 4.5 | 679 | Citations (PDF) |
| 31 | Impact of oncogenic pathways on evasion of antitumour immune responses | 33.8 | 658 | Citations (PDF) |
| 32 | The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies | 26.5 | 736 | Citations (PDF) |
| 33 | Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity | 3.1 | 160 | Citations (PDF) |
| 34 | Mechanisms of Tumor Cell–Intrinsic Immune Evasion | 2.7 | 100 | Citations (PDF) |
| 35 | A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors | 1.3 | 15 | Citations (PDF) |
| 36 | Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab 2018, 6, | | 58 | Citations (PDF) |
| 37 | Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer 2018, 6, | | 14 | Citations (PDF) |
| 38 | Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance | 4.4 | 19 | Citations (PDF) |
| 39 | Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity | 1.3 | 42 | Citations (PDF) |
| 40 | The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment | 5.9 | 193 | Citations (PDF) |
| 41 | Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy | 28.7 | 1,404 | Citations (PDF) |
| 42 | The Microbiota: A New Variable Impacting Cancer Treatment Outcomes | 4.5 | 21 | Citations (PDF) |
| 43 | Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting | 2.7 | 47 | Citations (PDF) |
| 44 | First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies | 4.5 | 303 | Citations (PDF) |
| 45 | Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell, 2017, 171, 934-949.e16 | 23.8 | 2,198 | Citations (PDF) |
| 46 | Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma | 1.0 | 19 | Citations (PDF) |
| 47 | Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk | 3.3 | 70 | Citations (PDF) |
| 48 | Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy 2016, 4, | | 485 | Citations (PDF) |
| 49 | Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma | 5.3 | 383 | Citations (PDF) |
| 50 | Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial 2016, 4, | | 32 | Citations (PDF) |
| 51 | Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy | 6.8 | 1,455 | Citations (PDF) |
| 52 | A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma | 1.6 | 7 | Citations (PDF) |
| 53 | Tumor-intrinsic oncogene pathways mediating immune avoidance | 3.3 | 141 | Citations (PDF) |
| 54 | Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy | 2.0 | 44 | Citations (PDF) |
| 55 | Innate immune signaling and regulation in cancer immunotherapy | 10.2 | 377 | Citations (PDF) |
| 56 | Lymphatic vessels regulate immune microenvironments in human and murine melanoma | 6.8 | 198 | Citations (PDF) |
| 57 | The host STING pathway at the interface of cancer and immunity | 6.8 | 441 | Citations (PDF) |
| 58 | A new paradigm for tumor immune escape: β-catenin-driven immune exclusion 2015, 3, | | 138 | Citations (PDF) |
| 59 | Innate Immune Recognition of Cancer | 22.4 | 527 | Citations (PDF) |
| 60 | New perspectives on type I IFNs in cancer | 7.3 | 64 | Citations (PDF) |
| 61 | Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition | 4.5 | 144 | Citations (PDF) |
| 62 | T cell-NF-κB activation is required for tumor control in vivo 2015, 3, | | 82 | Citations (PDF) |
| 63 | Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity | 4.4 | 1,511 | Citations (PDF) |
| 64 | Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | 31.3 | 2,720 | Citations (PDF) |
| 65 | The STING pathway and the T cell-inflamed tumor microenvironment | 8.4 | 255 | Citations (PDF) |
| 66 | Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer | 4.5 | 188 | Citations (PDF) |
| 67 | The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment | 2.9 | 458 | Citations (PDF) |
| 68 | Fyn Expression Predicates Both Protective Immunity and Onset of Autoimmunity | 0.6 | 0 | Citations (PDF) |
| 69 | Primary Murine CD4+ T Cells Fail to Acquire the Ability to Produce Effector Cytokines When Active Ras Is Present during Th1/Th2 Differentiation | 1.5 | 2 | Citations (PDF) |
| 70 | Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma | 2.4 | 17 | Citations (PDF) |
| 71 | STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors | 16.6 | 2,079 | Citations (PDF) |
| 72 | Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma | 15.8 | 420 | Citations (PDF) |
| 73 | STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors | 16.6 | 1,857 | Citations (PDF) |
| 74 | Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study | 14.5 | 247 | Citations (PDF) |
| 75 | Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment 2014, 2, 3 | | 519 | Citations (PDF) |
| 76 | Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses | 28.7 | 268 | Citations (PDF) |
| 77 | A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma 2013, 1, 8 | | 36 | Citations (PDF) |
| 78 | Up-Regulation of PD-L1, IDO, and T
regs
in the Melanoma Tumor Microenvironment Is Driven by CD8
+
T Cells | 8.7 | 1,654 | Citations (PDF) |
| 79 | Rational combinations of immunotherapeutics that target discrete pathways 2013, 1, | | 68 | Citations (PDF) |
| 80 | Innate and adaptive immune cells in the tumor microenvironment | 14.4 | 3,896 | Citations (PDF) |
| 81 | The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma | 53.1 | 181 | Citations (PDF) |
| 82 | Type I interferon response and innate immune sensing of cancer | 8.4 | 338 | Citations (PDF) |
| 83 | Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment | 3.7 | 402 | Citations (PDF) |
| 84 | Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy | 2.0 | 45 | Citations (PDF) |
| 85 | CD40 ligation reverses T cell tolerance in acute myeloid leukemia | 6.8 | 65 | Citations (PDF) |
| 86 | Innate immune sensing of cancer: clues from an identified role for type I IFNs | 3.2 | 51 | Citations (PDF) |
| 87 | Ocular melanoma metastasis to the cervical spine | 1.0 | 9 | Citations (PDF) |
| 88 | Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) | 4.8 | 79 | Citations (PDF) |
| 89 | Cancer immunotherapy | 2.8 | 78 | Citations (PDF) |
| 90 | Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma | 1.6 | 45 | Citations (PDF) |
| 91 | Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells | 5.9 | 1,159 | Citations (PDF) |
| 92 | Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4+ T Cells | 1.5 | 23 | Citations (PDF) |
| 93 | Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy | 2.9 | 29 | Citations (PDF) |
| 94 | Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment | 3.7 | 141 | Citations (PDF) |
| 95 | β-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells–Phospholipase C-γ1 Phosphorylation | 0.8 | 53 | Citations (PDF) |
| 96 | Gene Signature in Melanoma Associated With Clinical Activity | 1.0 | 244 | Citations (PDF) |
| 97 | β-catenin does not regulate memory T cell phenotype | 22.8 | 37 | Citations (PDF) |
| 98 | Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy | 1.8 | 8 | Citations (PDF) |
| 99 | Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas | 1.0 | 15 | Citations (PDF) |
| 100 | Costimulatory and coinhibitory receptors in anti‐tumor immunity | 6.1 | 274 | Citations (PDF) |
| 101 | PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia modelBlood, 2009, 114, 1545-1552 | 3.6 | 398 | Citations (PDF) |
| 102 | A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma | 1.3 | 18 | Citations (PDF) |
| 103 | Molecular regulation of T‐cell anergy | 3.5 | 108 | Citations (PDF) |
| 104 | Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells | 1.0 | 14 | Citations (PDF) |
| 105 | Melanoma presenting as circulating tumor cells associated with failed angiogenesis | 1.0 | 5 | Citations (PDF) |
| 106 | Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma | 3.2 | 79 | Citations (PDF) |
| 107 | An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells | 1.5 | 11 | Citations (PDF) |
| 108 | Immune Suppression in the Tumor Microenvironment | 1.6 | 249 | Citations (PDF) |
| 109 | Immune resistance orchestrated by the tumor microenvironment | 6.1 | 432 | Citations (PDF) |
| 110 | T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-α | 14.4 | 279 | Citations (PDF) |
| 111 | A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma | 1.6 | 16 | Citations (PDF) |
| 112 | Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites | 3.2 | 130 | Citations (PDF) |
| 113 | An adenoviral vector for probing promoter activity in primary immune cells | 1.0 | 2 | Citations (PDF) |
| 114 | Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy | 1.7 | 12 | Citations (PDF) |
| 115 | Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responsesin vitro | 2.8 | 290 | Citations (PDF) |
| 116 | Metabolic Mechanisms of Tumor Resistance to T Cell Effector Function | 1.6 | 19 | Citations (PDF) |
| 117 | Actin Cytoskeleton Regulates Calcium Dynamics and NFAT Nuclear Duration | 1.5 | 63 | Citations (PDF) |
| 118 | Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma | 8.1 | 58 | Citations (PDF) |
| 119 | Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells | 5.3 | 61 | Citations (PDF) |
| 120 | Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic Malignancies | 12.3 | 45 | Citations (PDF) |
| 121 | Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy | 3.2 | 598 | Citations (PDF) |
| 122 | Negative Regulation of T-Cell Function by PD-1 | 1.1 | 84 | Citations (PDF) |
| 123 | Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes | 1.5 | 14 | Citations (PDF) |
| 124 | A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer | 1.9 | 41 | Citations (PDF) |
| 125 | B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism | 5.9 | 137 | Citations (PDF) |
| 126 | Gene Array and Protein Expression Profiles Suggest Post-transcriptional Regulation during CD8+ T Cell Differentiation | 1.3 | 29 | Citations (PDF) |
| 127 | Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma | 12.3 | 151 | Citations (PDF) |
| 128 | Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells | 0.8 | 105 | Citations (PDF) |
| 129 | Flt-3 Ligand and Sequential FL/Interleukin-2 in Patients With Metastatic Renal Carcinoma: Clinical and Biologic Activity | 1.6 | 27 | Citations (PDF) |
| 130 | Increasing Tumor Antigen Expression Overcomes “Ignorance” to Solid Tumors via Crosspresentation by Bone Marrow-Derived Stromal Cells | 16.6 | 226 | Citations (PDF) |
| 131 | The P815 Mastocytoma Tumor Model | 2.4 | 13 | Citations (PDF) |
| 132 | ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR METASTATIC RENAL CELL CARCINOMA | 3.3 | 31 | Citations (PDF) |
| 133 | Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A | 2.0 | 48 | Citations (PDF) |
| 134 | ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR METASTATIC RENAL CELL CARCINOMA | 3.3 | 4 | Citations (PDF) |
| 135 | Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells | 5.3 | 79 | Citations (PDF) |
| 136 | Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12 | 2.8 | 58 | Citations (PDF) |
| 137 | Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity 1999, 81, 428-437 | | 42 | Citations (PDF) |
| 138 | Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide | 8.1 | 21 | Citations (PDF) |
| 139 | Helper T Cell Differentiation Is Controlled by the Cell Cycle | 16.6 | 811 | Citations (PDF) |
| 140 | Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells | 2.0 | 31 | Citations (PDF) |
| 141 | The expression of mouse geneP1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen 1997, 70, 349-356 | | 65 | Citations (PDF) |
| 142 | Control of T lymphocyte signal transduction through clonal anergy | 2.8 | 35 | Citations (PDF) |
| 143 | Apoptosis Meets Signal Transduction: Elimination of a BAD Influence | 23.8 | 347 | Citations (PDF) |
| 144 | Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A 1996, 67, 303-310 | | 50 | Citations (PDF) |
| 145 | Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A | 2.4 | 47 | Citations (PDF) |
| 146 | From defined human tumor antigens to effective immunization? | 7.1 | 117 | Citations (PDF) |
| 147 | A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3 | 2.4 | 344 | Citations (PDF) |
| 148 | Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. | 5.3 | 132 | Citations (PDF) |
| 149 | Regulation of anti-immunoglobulin-induced B lymphoma growth arrest by transforming growth factor β1 and dexamethasone | 2.0 | 9 | Citations (PDF) |
| 150 | Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance) | 3.1 | 1 | Citations (PDF) |
